Tag Archives: Actelion

Weekly market opportunities in T-Advisor: the best on March, 28th

T-Advisor updates weekly a list of market opportunities from several stock exchanges around the world. We sum up a selection of the best ones:


  • Actelion (Switzerland). A biopharmaceutical company specialised in drugs and treatments for rare diseases.

Actelion main figures in T-Advisor

Actelion chart in T-Advisor

  • Ementor (Oslo). An IT infrastructure company that sells, installs and support products from other enterprises.

Ementor main figures in T-Advisor

Ementor chart in T-Advisor


  • Industrias CH (Mexico). An iron and steel producer with factories in Mexico, Canada and USA.

Industrias CH main figures in T-Advisor

Industrias CH chart in T-Advisor

  • Ambev (Sao Paulo). The largest brewery in Latin America and the fifth in the world.

Ambev main figures in T-Advisor

Ambev chart in T-Advisor


  • Singapore Technologies Engineering (Singapore). An integrated engineering group in the aerospace, electronics, military contracting and marine sectors.

Singapore Technologies Engineering main figures in T-Advisor

Singapore Technologies Engineering chart in T-Advisor

  • Daiwa House Industry (Tokyo). Japan’s largest homebuilder, specializing in prefabricated houses.

Daiwa House Industry main figures in T-Advisor

Daiwa House Industry chart in T-Advisor

Find more opportunities from the main exchanges in the world on our module “Market opportunities” in T-Advisor.

Market opportunities by T-Advisor: Actelion

T-Advisor, through its tool Market Opportunities, has detected the company Actelion, listed in the Swiss Exchange, as an opportunity for investment.

These are the main figures about performances and volatility in the last years:

Actelion main figures in T-Advisor

The technical analysis reveals also more data:

Actelion technical analysis in T-Advisor

The chart shows the evolution i the last year:

Actelion chart in T-Advisor

Finally, the risk analysis is as follows:

Actelion risk analysis in T-Advisor

Actelion is a biopharmaceutical company focused on the discovery, development  and commercialization of drugs for diseases with significant unmet medical needs. Founded in 1997, it has more than 2,400 workers in over 30 countries. The company bought in 2006 CoTherix to enter the American market.

The revenues in 2013 increased a 4%, till CHF 1,784 million and the net income reached CHF 509 million, a 13% more. After a decreasing trend till 2012, the stock has begun to go up and has multiplied three times the price in the last two years.